CONCLUSION: ADAM-101, when combined with pharmacotherapy, improved neural synchrony in pediatric ADHD, as evidenced by increased prefrontal TGC. This exploratory trial supports the potential of digital therapeutics as adjunctive interventions targeting neurophysiological mechanisms of attentional control. Larger studies are needed to validate these preliminary results.
